Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara (CERT – Research Report) on April 11. The company’s shares closed ...

Leerink Partners analyst Michael Cherny maintained a Hold rating on Envista Holdings (NVST – Research Report) on April 10 and set a price ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. According to TipRanks, Risinger is a 5-star analyst with an average return of 9 ...

Private equity investor Jeffrey Leerink, of Leerink Partners, is one of the two lead private developers of the Hanscom expansion. For years, Leerink has served as a close private-equity adviser to ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from Outperform to Market Perform. Analyst Price Forecast Suggests 136.79% Upside ...

For a detailed understanding, readers are encouraged to review the full conference call transcript. Joe Schwartz, Equity Research Team, Leerink Partners: Okay. Welcome everyone. It’s my pleasure to ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.